Geneticists hunt control patterns The Human Epigenome Project will look for patterns in our ‘life code’ that are associated with gene regulation but are also implicated in causing disease. Researchers at Epigenomics AG in Berlin and the Sanger Institute in Cambridge will take part in the five-year study.
Faster Entry Sought for Generics Despite efforts to speed up approval of generic drugs, Americans still spend billions extra for prescriptions because of delays engineered by brand-name pharmaceutical companies. Pending legislation could help.
Biotech IPO Pipeline Fills Up With the biotech sector surging this year, private companies in the field see a chance to pull in some cash. But follow some key steps before buying.
Financing On Target For A Stellar Year It’s beginning to look a lot like 2001 – or better. In the first nine months of 2003, biotech companies raised nearly $11.8 billion in new funds (excluding revenues and payments from corporate partners), putting the sector on track for at least equaling – if not topping -the […]
GM crops in Brazil Brazilian farmers will embrace genetically modified crops, unless European consumers pay them not to …
Affymetrix sells new gene chip / Chip represents full human genome Affymetrix Inc. of Santa Clara won the race Thursday to market a single gene chip packed with fragments from each of the 35,000 known genes that make up the human genome. But two other Bay area companies, Agilent Technologies of Palo Alto and Applied […]
Wound drug ‘could speed healing’ Early tests of the drug suggests it may more than halve the healing time in some cases.
Genentech Will Ride Out Drug Failure Even Genentech gets bad news once in a while. But the failure of clinical trials of Tarceva, a pill being developed with tiny OSI Pharmaceuticals of Melville, N.Y, as a first-line treatment in non-small cell lung cancer was widely expected. The real test of the drug will come from […]
Genentech’s CEO on Big Pharma’s Issues Arthur Levinson tackles drug pricing, patent disputes, consumer marketing, and stem-cell research
FDA’s McClellan Calls for More Sharing of Drug R&D Costs The U.S. is bearing a disproportionate share of drug research and development costs for medicines used globally, FDA commissioner Mark McClellan said Thursday. He called for more equitable cost sharing and price setting. ‘If we do not find better ways to share the burden of […]